In 2011, Moskwa et al. have demonstrated that breast cancer cells overexpressing miR-182 are more sensitive to IR and PARP inhibitors via BRCA1 targeting and impairment of DNA repair. This evidence concerns the gene PARP1 and breast carcinoma.